Vertex Pharmaceuticals

VRTXintermediary

Vertex Pharmaceuticals dominates the cystic fibrosis market with Trikafta and is expanding into gene editing (Casgevy for sickle cell), non-opioid pain (suzetrigine), and kidney disease. Its CF franchise generates massive cash flow to fund pipeline diversification.

共有:

⇄ Compare

製品と売上

製品別売上シェア

売上内訳 ($11.2B)

静的データ（リアルタイム財務ロード中…）

Cystic Fibrosis (Trikafta) (78%)

Gene Therapy (Casgevy) (8%)

Other Products & Collaborations (14%)

セグメント構成と主要顧客

製品詳細

Trikafta / Kaftrio65%

Triple-combination CFTR modulator for cystic fibrosis — standard of care

Casgevy (exa-cel)8%

CRISPR-based gene therapy for sickle cell disease and beta-thalassemia

Pain Pipeline (VX-548, suzetrigine)10%

Non-opioid NaV1.8 pain inhibitor for acute and neuropathic pain

サプライチェーン関係

競合他社

Eli Lilly and Company

Pain therapeutics pipeline

影響: Competing in non-opioid pain

Regeneron Pharmaceuticals

Gene editing and rare disease

影響: Competing in genetic medicine

Pfizer Inc.

Gene therapy and rare disease

影響: Limited overlap

マクロ・市場概況

제약 / 바이오セクターニュース

GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집

GLP-1 시장 규모 (2030E)

$150B

mRNA 암백신 임상 성공률

+49% 재발 위험 감소

AI 신약개발 단계

임상 2상 진입

PFE/MRNA 52주 변화

-30% ~ -45%

次の主要イベント

◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)◆MRNA 암백신 FDA BLA 제출 예정◆REGN EYLEA HD 유럽 허가 결과

AI分析

Vertex PharmaceuticalsのAIサプライチェーン分析を受けるには「AI分析を取得」をクリックしてください。

企業情報

本社所在地

Boston, Massachusetts, USA

設立

1989

従業員数

10,400+

ウェブサイト

vrtx.com

セクター概況 — 제약 / 바이오

セクターニュース